Free Trial
→ Elon Musk about to bankrupt Amazon, Microsoft & Google? (From Brownstone Research) (Ad)tc pixel
NASDAQ:BCAX

Bicara Therapeutics Q3 2026 Earnings Date & Estimates

Bicara Therapeutics logo
$8.63 -0.50 (-5.43%)
As of 10:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bicara Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Bicara Therapeutics in Q3 2026

Bicara Therapeutics is expected to post earnings of -$0.84 per share. In the same quarter a year earlier Bicara Therapeutics reported -$0.67 per share. Bicara Therapeutics last reported on August 11, 2026, posting -$0.82 per share and missing the -$0.8198 consensus estimate. Bicara Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.84
Prior-Year EPS
-$0.67

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.82 (Missed by -$0.0002)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Bicara Therapeutics Q3 2026 Earnings FAQ

Bicara Therapeutics (NASDAQ:BCAX) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Bicara Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Bicara Therapeutics to post earnings of -$0.84 per share for Q3 2026.

Bicara Therapeutics Earnings Headlines

Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3393152/0/en/bicara-therapeutics-to-report-third-quarter-2026-financial-results-and-business-updates-on-november-9-2026-at-8-30-am-et.html
Bicara Therapeutics (NASDAQ:BCAX) Cut to "Sell" at The Goldman Sachs Group
November 2 at 2:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173050
Government Document Reveals Plan To Control Your Money (it will disturb you)
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel
November 2 at 1:00 AM  |  Weiss Ratings (Ad)
Bicara Therapeutics (NASDAQ:BCAX) Sees Large Volume Increase - Here's What Happened
November 1 at 4:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31172402
Wedbush Adjusts Price Target on Bicara Therapeutics to $24 From $33, Maintains Outperform Rating
October 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/wedbush-adjusts-price-target-bicara-092706680.html
Analysts Offer Insights on NA Companies: Bicara Therapeutics Inc. (BCAX) and Microsoft (MSFT)
October 28, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MSFT-Q/pressreleases/8490304/analysts-offer-insights-on-na-companies-bicara-therapeutics-inc-bcax-and-microsoft-msft/
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX) is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression. The company has been evaluating ficerafusp alfa in clinical studies involving head and neck cancers, including in combination with pembrolizumab.

Bicara is headquartered in the United States and is advancing its pipeline through clinical development and research collaborations. As an emerging biotechnology company, its activities are primarily focused on developing potential cancer treatments rather than marketing approved commercial products.

View Bicara Therapeutics Profile
Earnings Tools